174 related articles for article (PubMed ID: 30843385)
1. Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.
Dabbish E; Ponte F; Russo N; Sicilia E
Inorg Chem; 2019 Mar; 58(6):3851-3860. PubMed ID: 30843385
[TBL] [Abstract][Full Text] [Related]
2. A computational mechanistic investigation into the reduction of Pt(iv) prodrugs with two axial chlorides by biological reductants.
Ejehi Z; Ariafard A
Chem Commun (Camb); 2017 Jan; 53(8):1413-1416. PubMed ID: 28079213
[TBL] [Abstract][Full Text] [Related]
3. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
Sinisi M; Intini FP; Natile G
Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
[TBL] [Abstract][Full Text] [Related]
4. Reduction of ormaplatin and cis-diamminetetrachloroplatinum(iv) by ascorbic acid and dominant thiols in human plasma: kinetic and mechanistic analyses.
Dong J; Ren Y; Huo S; Shen S; Xu J; Tian H; Shi T
Dalton Trans; 2016 Jul; 45(28):11326-37. PubMed ID: 27327648
[TBL] [Abstract][Full Text] [Related]
5. Insights from Computations on the Mechanism of Reduction by Ascorbic Acid of Pt
Ponte F; Russo N; Sicilia E
Chemistry; 2018 Jul; 24(38):9572-9580. PubMed ID: 29723436
[TBL] [Abstract][Full Text] [Related]
6. Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.
Zhang JZ; Wexselblatt E; Hambley TW; Gibson D
Chem Commun (Camb); 2012 Jan; 48(6):847-9. PubMed ID: 22124352
[TBL] [Abstract][Full Text] [Related]
7. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
8. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
[TBL] [Abstract][Full Text] [Related]
9. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
10. Iodido equatorial ligands influence on the mechanism of action of Pt(IV) and Pt(II) anti-cancer complexes: A DFT computational study.
Scoditti S; Vigna V; Dabbish E; Sicilia E
J Comput Chem; 2021 Apr; 42(9):608-619. PubMed ID: 33469953
[TBL] [Abstract][Full Text] [Related]
11. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.
Ritacco I; Mazzone G; Russo N; Sicilia E
Inorg Chem; 2016 Feb; 55(4):1580-6. PubMed ID: 26812023
[TBL] [Abstract][Full Text] [Related]
14. A multi-methodological inquiry of the behavior of cisplatin-based Pt(IV) derivatives in the presence of bioreductants with a focus on the isolated encounter complexes.
Corinti D; Crestoni ME; Fornarini S; Dabbish E; Sicilia E; Gabano E; Perin E; Osella D
J Biol Inorg Chem; 2020 Jun; 25(4):655-670. PubMed ID: 32296997
[TBL] [Abstract][Full Text] [Related]
15. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
16. Understanding intrinsically irreversible, non-Nernstian, two-electron redox processes: a combined experimental and computational study of the electrochemical activation of platinum(IV) antitumor prodrugs.
McCormick MC; Keijzer K; Polavarapu A; Schultz FA; Baik MH
J Am Chem Soc; 2014 Jun; 136(25):8992-9000. PubMed ID: 24853204
[TBL] [Abstract][Full Text] [Related]
17. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
Varbanov HP; Valiahdi SM; Kowol CR; Jakupec MA; Galanski MS; Keppler BK
Dalton Trans; 2012 Dec; 41(47):14404-14415. PubMed ID: 22886297
[TBL] [Abstract][Full Text] [Related]
18. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
19. Platinum(IV) Prodrugs.
Venkatesh V; Sadler PJ
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and mechanism for reduction of the anticancer prodrug trans,trans,trans-[PtCl2(OH)2(c-C6H11NH2)(NH3)] (JM335) by thiols.
Lemma K; Shi T; Elding LI
Inorg Chem; 2000 Apr; 39(8):1728-34. PubMed ID: 12526561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
